Table 2.
Open in new tab

Hazard ratio and percentage of events in initial responder and non-responder patients further stratified by the change in albuminuria from Month 3 to Month 12

No. of patientsNo. of events (%)Hazard ratio (95% CI)P-value
End-stage renal disease or doubling of serum creatinine
Responders
 Sustained response12334 (27.6)Ref (1.0)
 Enhanced response17422 (12.6)0.42 (0.23–0.77)0.005
 Escaped response9124 (26.4)2.03 (1.13–3.66)0.019
Non-responders
 Sustained non-response28784 (29.3)Ref (1.0)
 Enhanced non-response21277 (36.3)2.97 (2.05–4.30)<0.0001
 Switch to response18346 (25.1)0.64 (0.43–0.94)0.024
End-stage renal disease
Responders
 Sustained response12321 (17.1)Ref (1.0)
 Enhanced response17415 (20.3)0.34 (0.15–0.77)0.009
 Escaped response9113 (14.3)1.68 (0.78–3.63)0.185
Non-responders
 Sustained non-response28748 (16.7)Ref (1.0)
 Enhanced non-response21244 (20.8)3.96 (2.33–6.74)<0.0001
 Switch to response18325 (13.7)0.65 (0.38–1.11)0.118
Doubling of serum creatinine
Responders
 Sustained response12324 (19.5)Ref (1.0)
 Enhanced response17418 (10.4)0.35 (0.15–0.78)0.011
 Escaped response9113 (14.3)2.70 (1.30–5.61)0.008
Non-responders
 Sustained non-response28772 (25.1)Ref (1.0)
 Enhanced non-response21267 (31.6)2.97 (2.00–4.41)<0.0001
 Switch to response18332 (17.5)0.50 (0.32–0.78)0.002
No. of patientsNo. of events (%)Hazard ratio (95% CI)P-value
End-stage renal disease or doubling of serum creatinine
Responders
 Sustained response12334 (27.6)Ref (1.0)
 Enhanced response17422 (12.6)0.42 (0.23–0.77)0.005
 Escaped response9124 (26.4)2.03 (1.13–3.66)0.019
Non-responders
 Sustained non-response28784 (29.3)Ref (1.0)
 Enhanced non-response21277 (36.3)2.97 (2.05–4.30)<0.0001
 Switch to response18346 (25.1)0.64 (0.43–0.94)0.024
End-stage renal disease
Responders
 Sustained response12321 (17.1)Ref (1.0)
 Enhanced response17415 (20.3)0.34 (0.15–0.77)0.009
 Escaped response9113 (14.3)1.68 (0.78–3.63)0.185
Non-responders
 Sustained non-response28748 (16.7)Ref (1.0)
 Enhanced non-response21244 (20.8)3.96 (2.33–6.74)<0.0001
 Switch to response18325 (13.7)0.65 (0.38–1.11)0.118
Doubling of serum creatinine
Responders
 Sustained response12324 (19.5)Ref (1.0)
 Enhanced response17418 (10.4)0.35 (0.15–0.78)0.011
 Escaped response9113 (14.3)2.70 (1.30–5.61)0.008
Non-responders
 Sustained non-response28772 (25.1)Ref (1.0)
 Enhanced non-response21267 (31.6)2.97 (2.00–4.41)<0.0001
 Switch to response18332 (17.5)0.50 (0.32–0.78)0.002

Covariates: age, gender, race, baseline eGFR, albuminuria, systolic and diastolic blood pressure, haemoglobin, HbA1c and the change in systolic blood pressure and potassium from Month 3 to Month 12.

Table 2.
Open in new tab

Hazard ratio and percentage of events in initial responder and non-responder patients further stratified by the change in albuminuria from Month 3 to Month 12

No. of patientsNo. of events (%)Hazard ratio (95% CI)P-value
End-stage renal disease or doubling of serum creatinine
Responders
 Sustained response12334 (27.6)Ref (1.0)
 Enhanced response17422 (12.6)0.42 (0.23–0.77)0.005
 Escaped response9124 (26.4)2.03 (1.13–3.66)0.019
Non-responders
 Sustained non-response28784 (29.3)Ref (1.0)
 Enhanced non-response21277 (36.3)2.97 (2.05–4.30)<0.0001
 Switch to response18346 (25.1)0.64 (0.43–0.94)0.024
End-stage renal disease
Responders
 Sustained response12321 (17.1)Ref (1.0)
 Enhanced response17415 (20.3)0.34 (0.15–0.77)0.009
 Escaped response9113 (14.3)1.68 (0.78–3.63)0.185
Non-responders
 Sustained non-response28748 (16.7)Ref (1.0)
 Enhanced non-response21244 (20.8)3.96 (2.33–6.74)<0.0001
 Switch to response18325 (13.7)0.65 (0.38–1.11)0.118
Doubling of serum creatinine
Responders
 Sustained response12324 (19.5)Ref (1.0)
 Enhanced response17418 (10.4)0.35 (0.15–0.78)0.011
 Escaped response9113 (14.3)2.70 (1.30–5.61)0.008
Non-responders
 Sustained non-response28772 (25.1)Ref (1.0)
 Enhanced non-response21267 (31.6)2.97 (2.00–4.41)<0.0001
 Switch to response18332 (17.5)0.50 (0.32–0.78)0.002
No. of patientsNo. of events (%)Hazard ratio (95% CI)P-value
End-stage renal disease or doubling of serum creatinine
Responders
 Sustained response12334 (27.6)Ref (1.0)
 Enhanced response17422 (12.6)0.42 (0.23–0.77)0.005
 Escaped response9124 (26.4)2.03 (1.13–3.66)0.019
Non-responders
 Sustained non-response28784 (29.3)Ref (1.0)
 Enhanced non-response21277 (36.3)2.97 (2.05–4.30)<0.0001
 Switch to response18346 (25.1)0.64 (0.43–0.94)0.024
End-stage renal disease
Responders
 Sustained response12321 (17.1)Ref (1.0)
 Enhanced response17415 (20.3)0.34 (0.15–0.77)0.009
 Escaped response9113 (14.3)1.68 (0.78–3.63)0.185
Non-responders
 Sustained non-response28748 (16.7)Ref (1.0)
 Enhanced non-response21244 (20.8)3.96 (2.33–6.74)<0.0001
 Switch to response18325 (13.7)0.65 (0.38–1.11)0.118
Doubling of serum creatinine
Responders
 Sustained response12324 (19.5)Ref (1.0)
 Enhanced response17418 (10.4)0.35 (0.15–0.78)0.011
 Escaped response9113 (14.3)2.70 (1.30–5.61)0.008
Non-responders
 Sustained non-response28772 (25.1)Ref (1.0)
 Enhanced non-response21267 (31.6)2.97 (2.00–4.41)<0.0001
 Switch to response18332 (17.5)0.50 (0.32–0.78)0.002

Covariates: age, gender, race, baseline eGFR, albuminuria, systolic and diastolic blood pressure, haemoglobin, HbA1c and the change in systolic blood pressure and potassium from Month 3 to Month 12.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close